Collegium Pharmaceutical, Inc.COLLNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
0.00%
↓ 100% below average
Average (39q)
3.08%
Historical baseline
Range
High:165.32%
Low:-100.00%
Volatility
8618.4%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | 0.00% |
| Q3 2023 | 0.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | 0.00% |
| Q4 2022 | 0.00% |
| Q3 2022 | 0.00% |
| Q2 2022 | -100.00% |
| Q1 2022 | 147.55% |
| Q4 2021 | 10.97% |
| Q3 2021 | -58.12% |
| Q2 2021 | 18.16% |
| Q1 2021 | 18.53% |
| Q4 2020 | 15.46% |
| Q3 2020 | -14.12% |
| Q2 2020 | -6.49% |
| Q1 2020 | 11.18% |
| Q4 2019 | -3.73% |
| Q3 2019 | 1.30% |
| Q2 2019 | -17.81% |
| Q1 2019 | 33.04% |
| Q4 2018 | 17.93% |
| Q3 2018 | -14.75% |
| Q2 2018 | -1.37% |
| Q1 2018 | 3.37% |
| Q4 2017 | 6.04% |
| Q3 2017 | -5.05% |
| Q2 2017 | 2.30% |
| Q1 2017 | -36.06% |
| Q4 2016 | 2.37% |
| Q3 2016 | -24.34% |
| Q2 2016 | 5.88% |
| Q1 2016 | 165.32% |
| Q4 2015 | -54.41% |